Opinion statement
Treatment with the tyrosine kinase inhibitor (TKI), imatinib is the standard first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Unfortunately, acquired c-kit mutations cause secondary resistance to imatinib in a median of 18–24 months. Sunitinib and regorafenib are multi-kinase inhibitors that can be used as second-line or third-line therapy in imatinib-resistant or -intolerant GISTs, respectively. Ripretinib (a switch-control tyrosine kinase inhibitor) has recently been approved for fourth-line treatment in metastatic GIST. The TKI avapritinib has been approved for metastatic GIST harboring the imatinib-resistant PDGFRA exon 18 mutation. Although TKI therapies have revolutionized the treatment of metastatic GISTs, they cannot cure metastatic GISTs. Therefore, cytoreductive surgery is of considerable interest and has been accordingly investigated. Retrospective non-randomized studies demonstrated the feasibility and safety of continuous TKI therapy and surgical resection. Most studies demonstrate response to TKI therapy, completeness of resection, extent of disease, and surgical complexity as predictors of outcomes. Most TKIs can be stopped shortly before surgery and restarted shortly after. There is no known survival benefit from debulking operations or R2 resections and this should not be considered. However, debulking/palliative surgery may be necessary for patients with complications of hemorrhage, pain, or intestinal obstruction. SDH-deficient GISTs have an indolent natural history despite metastatic disease and may be another uncommon subgroup that would benefit from surgical debulking (R2 resection). At the time of operation, care should be taken to avoid tumor rupture. After surgical resection, patients should resume tyrosine kinase inhibitor (TKI) therapy as soon as possible and be monitored for disease progression. In all patients with metastatic GIST, the decision to pursue metastasectomy for GIST should be made in a multidisciplinary setting and be individualized according to patient age, comorbidities, functional status, symptoms, mutation status, extent of disease, completeness of resection, TKI response, and goals of the patient.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
•• Fairweather M, Balachandran VP, Li GZ, et al. Cytoreductive surgery for metastatic gastrointestinal stromal tumors treated with tyrosine kinase inhibitors: a 2-institutional analysis. Ann Surg. 2018;268(2):296–302. https://doi.org/10.1097/SLA.0000000000002281 Modern multi-institutional analysis of treatment of cytoreductive surgery for metastatic GIST.
Bamboat ZM, Dematteo RP. Metastasectomy for gastrointestinal stromal tumors. J Surg Oncol. 2014;109(1):23–7. https://doi.org/10.1002/jso.23451.
Corless CL. Gastrointestinal stromal tumors: what do we know now? 2014. https://doi.org/10.1038/modpathol.2013.173.
Blanke CD, Demetri GD, Von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620–5. https://doi.org/10.1200/JCO.2007.13.4403.
Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42(8):1093–103. https://doi.org/10.1016/j.ejca.2006.01.030.
Keung EZ, Raut CP, Rutkowski P. The landmark series: systemic therapy for resectable gastrointestinal stromal tumors. Ann Surg Oncol. 2020;27(10):3659–71. https://doi.org/10.1245/s10434-020-08869-w.
Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–80. https://doi.org/10.1056/NEJMoa020461.
Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99(1):42–7. https://doi.org/10.1002/jso.21160.
Quiroz HJ, Willobee BA, Sussman MS, et al. Pediatric gastrointestinal stromal tumors-a review of diagnostic modalities. Transl Gastroenterol Hepatol. 2018;3:54. Published 2018 Aug 8. https://doi.org/10.21037/tgh.2018.07.08.
Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302. https://doi.org/10.1016/S0140-6736(12)61857-1.
Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(7):923–34. https://doi.org/10.1016/S1470-2045(20)30168-6.
Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020;21(7):935–46. https://doi.org/10.1016/S1470-2045(20)30269-2.
Yang DY, Wang X, Yuan WJ, Chen ZH. Metastatic pattern and prognosis of gastrointestinal stromal tumor (GIST): a SEER-based analysis. Clin Transl Oncol. 2019;21(12):1654–62. https://doi.org/10.1007/s12094-019-02094-y.
DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51–8. https://doi.org/10.1097/00000658-200001000-00008.
Werewka-Maczuga A, Stępień M, Urbanik A. Evaluation of alterations in tumor tissue of gastrointestinal stromal tumor (GIST) in computed tomography following treatment with Imatinib. Polish J Radiol. 2017;82:817–26. https://doi.org/10.12659/PJR.902944.
Xia L, Zhang MM, Ji L, Li X, Wu XT. Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today. 2010;40(10):936–42. https://doi.org/10.1007/s00595-009-4171-x.
Kikuchi H, Hiramatsu Y, Kamiya K, et al. Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?. Transl Gastroenterol Hepatol. 2018;3:14. Published 2018 Mar 5. https://doi.org/10.21037/tgh.2018.02.02.
Du CY, Zhou Y, Song C, et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Eur J Cancer. 2014;50(10):1772–8. https://doi.org/10.1016/j.ejca.2014.03.280.
Raut CP, Wang Q, Manola J, et al. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol. 2010;17(2):407–15. https://doi.org/10.1245/s10434-009-0784-y.
Yeh CN, Wang SY, Tsai CY, et al. Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: a prospective cohort study. Int J Surg. 2017;39:30–6. https://doi.org/10.1016/j.ijsu.2017.01.045.
Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg. 2007;245(3):341–6. https://doi.org/10.1097/01.sla.0000242710.36384.1b.
DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007;245(3):347–52. https://doi.org/10.1097/01.sla.0000236630.93587.59.
Mussi C, Ronellenfitsch U, Jakob J, et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol. 2010;21(2):403–8. https://doi.org/10.1093/annonc/mdp310.
Bauer S, Rutkowski P, Hohenberger P, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol. 2014;40(4):412–9. https://doi.org/10.1016/j.ejso.2013.12.020.
• Fairweather M, Cavnar MJ, Li GZ, Bertagnolli MM, DeMatteo RP, Raut CP. Prediction of morbidity following cytoreductive surgery for metastatic gastrointestinal stromal tumour in patients on tyrosine kinase inhibitor therapy. Br J Surg. 2018;105(6):743–50. https://doi.org/10.1002/bjs.10774 This article outlines a proposed calculator to help assist the clinician in patients selection.
Sato S, Tsujinaka T, Yamamoto K, et al. Primary surgery as a frontline treatment for synchronous metastatic gastrointestinal stromal tumors: an analysis of the Kinki GIST registry. Surg Today. 2016;46(9):1068–75. https://doi.org/10.1007/s00595-015-1282-4.
Sato S, Tsujinaka T, Masuzawa T, et al. Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry. Surg Today. 2017;47(1):58–64. https://doi.org/10.1007/s00595-016-1351-3.
Willobee BA, Quiroz HJ, Sussman MS, Thorson CM, Sola JE, Perez EA. Current treatment strategies in pediatric gastrointestinal stromal cell tumor. Transl Gastroenterol Hepatol. 2018;3(August):53-53. https://doi.org/10.21037/tgh.2018.07.09.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Jennifer A. Yonkus declares that she has no conflict of interest. Roberto Alva-Ruiz declares that he has no conflict of interest. Travis E. Grotz declares that that he has no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Sarcoma
Rights and permissions
About this article
Cite this article
Yonkus, J.A., Alva-Ruiz, R. & Grotz, T.E. Surgical Management of Metastatic Gastrointestinal Stromal Tumors. Curr. Treat. Options in Oncol. 22, 37 (2021). https://doi.org/10.1007/s11864-021-00837-0
Accepted:
Published:
DOI: https://doi.org/10.1007/s11864-021-00837-0